Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 413 participants.

Also called NCT02642159

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 413 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02642159
  • EudraCT 2015-001934-19
Other papers using this trial's data
  • Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial Diabetes, obesity & metabolism, 2018-06 DOI, PubMed 29436756, PMC5969299 In the PMC Open Access subset under CC BY-NC-ND.
  • Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol Cardiovascular diabetology, 2020-02-08 DOI, PubMed 32035487, PMC7007683 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Brazil, Finland, Germany, Israel, Italy, Kuwait, Lebanon, Norway, Sweden, Switzerland, Türkiye, United Arab Emirates, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02642159. Randomized; no masking; primary purpose treatment. Start 2016-03-15 (registry gives no type); primary completion 2017-03-22 (actual). Results posted on 2018-05-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
Condition
Dyslipidemia
Intervention (Drug)
Alirocumab
Intervention (Drug)
Statins
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Fenofibrate
Intervention (Drug)
Nicotinic acid
Intervention (Drug)
Omega-3 fatty acids
Intervention (Drug)
Antihyperglycemic Drug
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02642159
Content hash
e33de44e8de85a35ed01b3c3ebe9e5d1cf03e5c3ff76e9cd861b8e84d2d2ea2f